title: Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis.
abstract: OBJECTIVE
  To assess the efficacy of sildenafil for erectile dysfunction (ED) in patients on haemodialysis (HD) or peritoneal dialysis (PD), as men with end-stage renal disease (ESRD) often have sexual dysfunction (up to 82% among those on chronic dialysis).
  
  
  METHODS
  Forty-one patients with ED and in ESRD participated in an open-label prospective study. Thirty patients on HD and 11 on PD were asked to complete the International Index of Erectile Function (IIEF) and Fugl-Meyer life-satisfaction scale before and after sildenafil treatment. A total score in the erectile function domain of < or = 25 was accepted as indicating ED. All patients were started on a 25-mg dose, which was increased to 50 mg if there was no response after two trials. In addition, the overall efficacy question was used to evaluate satisfaction, and patients reported any side-effects during treatment.
  
  
  RESULTS
  The erectile function and intercourse satisfaction domains improved significantly in both groups (P < 0.01). After sildenafil treatment, two-thirds of those on HD (20/30) and nine of the 11 on PD recovered their erectile function. The pretreatment scores on the IIEF and four domains (except sexual desire) of those responding were significantly higher than in those not responding (P < 0.05). The satisfaction rate on the overall efficacy question was 80% and 82% for the HD and PD groups, respectively. At least one side-effect was seen in 17 patients (43%); one had severe hypotension in the PD group. Overall, mild headache (seven patients, 18%) and flushing (12, 30%) were reported most often.
  
  
  CONCLUSIONS
  Sildenafil is a safe and satisfactory drug for improving erectile function in patients with ESRD. Patients were satisfied whether treated by HD or PD. Pretreatment scores on the IIEF may be useful for predicting the success of treatment.
authors.affiliation: Department of Nephrology, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: YeniçerioGlu
authors.forename: A
authors.initials: A
authors.lastname: Kefi
authors.forename: G
authors.initials: G
authors.lastname: Aslan
authors.forename: C
authors.initials: C
authors.lastname: Cavdar
authors.forename: A A
authors.initials: AA
authors.lastname: Esen
authors.forename: T
authors.initials: T
authors.lastname: Camsari
authors.forename: I
authors.initials: I
authors.lastname: Celebi
mesh_terms: D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010530:Peritoneal Dialysis; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011687:Purines; D011788:Quality of Life; D006435:Renal Dialysis; D012725:Sexual Behavior; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate